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Abstract
Background Recently, unprecedented drops in breast cancer
incidence have been reported for populations of mostly White
European descent. Incidence patterns in non-White racial/
ethnic groups are less described. Therefore, we examined
population-based breast cancer incidence trends separately for
US Asian/Pacific Islander, Hispanic, African-American, and non-
Hispanic White women by etiologically relevant tumor subtype
characteristics, including hormone receptor status, histology,
size, and in situ behavior.
Methods We obtained breast cancer data from 13 Surveillance,
Epidemiology, and End Results (SEER) cancer registries to
calculate age-adjusted incidence rates and trends, stratified by
race/ethnicity and tumor subtype for the period 1992–2004.
Detailed analyses were limited to women 50 years old or older.
Joinpoint regression was used to assess incidence trends by
annual quarter of diagnosis.
Results Between 2001 and 2004, incidence rates of invasive
breast cancer in women 50 years old or older declined
appreciably among Asians/Pacific Islanders (-8.5%) and
Hispanics (-2.9%) and were stable in African-Americans
(+0.5%), reductions substantially lower than those observed
among non-Hispanic Whites (-14.3%). In Asian/Pacific Islander
women, perceptible but statistically nonsignificant decreases
were observed for hormone receptor-positive, lobular, and small
tumors only. Rates of hormone receptor-negative tumors
increased among African-Americans (26.1%) and Hispanics
(26.9%) during 2001–2004. Incidence trends in most groups,
except African-American women, peaked between 1999 and
mid-2002. Rates of in situ cancer remained stable in all groups.
Conclusion Recently reported reductions in breast cancer
incidence varied considerably by race/ethnicity. These patterns
are consistent with documented racial/ethnic differences in the
prevalence and discontinuation of hormone therapy (HT) after
July 2002 but do not correspond as well to patterns of
mammography use in these groups. The data presented in this
analysis provide further evidence that population-level HT use is
a major influence on population-level rates of particular breast
cancer subtypes, especially receptor-positive tumors.
Introduction
Recent reports have documented sudden, unprecedented
declines in the incidence of breast cancer, particularly for inva-
sive, estrogen receptor-positive (ER+) tumors diagnosed in
women 50 years old or older [1-7]. Thus far, substantial drops
have been observed in the US, Germany, New Zealand, and
Canada [1-3,8-10] but not in the Netherlands, Norway, or
Sweden [10]. In populations reporting a decrease, gradual
incidence declines began as early as 1999 but accelerated in
2002 after the early and widely publicized termination of the
Women's Health Initiative (WHI) estrogen/progestin arm, in
which the experimental group experienced increased risks of
breast cancer [11]. The US incidence reductions generally
have been attributed to two factors: (a) the well-documentedPage 1 of 12
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ning in the second half of 2002 [1-3,12-16] and (b) the possi-
ble effects of saturation in mammographic screening
programs [2,5]. However, it is difficult to quantify precisely the
relative impacts of these phenomena on breast cancer inci-
dence because the US does not employ a comprehensive
health tracking resource and must therefore rely on ecologic
assessments for understanding population cancer patterns.
To date, recent incidence reductions have been well charac-
terized for populations of mostly or entirely European descent
(for example, non-Hispanic White women) but remain incom-
plete for populations of other races/ethnicities, especially by
tumor subtype for which incidence patterns vary considerably,
possibly because of etiologic heterogeneity [17-21]. One
report did suggest that overall age-adjusted invasive breast
cancer rates in US African-American women were essentially
unchanged between 2001 and 2004 [22]. To better under-
stand whether the recent incidence drops observed in non-
Hispanic White women were also observed in women of non-
White races/ethnicities, we examined trends in invasive and in
situ female breast cancer by tumor hormone receptor status,
histology, and size among US Asian/Pacific Islander, Hispanic,
and African-American women as compared with non-Hispanic
White women.
Materials and methods
We obtained population-based breast cancer (International
Classification of Diseases for Oncology, 3rd Edition [ICD-O-
3], sites 50.0 to 50.9) incidence data from the Surveillance,
Epidemiology, and End Results (SEER) program of the
National Cancer Institute (Bethesda, MD, USA), including
321,157 cases of invasive and 66,074 cases of in situ dis-
ease diagnosed between 1992 and 2004 in SEER-13 catch-
ment regions (Alaska natives; Connecticut; Hawaii; Iowa; New
Mexico; rural Georgia; Utah; the metropolitan areas surround-
ing Atlanta, GA; Detroit, MI; Los Angeles, CA; San Francisco-
Oakland, CA; San Jose-Monterey, CA; and Seattle-Puget
Sound, WA). Altogether, the population covered by these 13
registries comprises 14% of the entire US population and is
representative of the larger population with respect to educa-
tional and socioeconomic status but over-represents urban
areas and foreign-born populations [23]. Demographic and
tumor information for each incident case of breast cancer was
abstracted directly from medical records [24]. Population
denominator estimates were obtained from the SEER program
and based on US census data.
Incidence analyses included all diagnoses reported in women
between the years 1992, the first year that data from the large
and diverse Los Angeles and San Jose-Monterey SEER
regions were available, and 2004, the most recent year that
SEER data were available. All analyses were limited to women
more than 50 years old because (a) post-2002 incidence
declines were not observed in the 5-year age groups under
age 50 (data not shown); (b) women under age 50 are more
heterogeneous with respect to menopausal status, HT use,
and regularity of mammographic screening; and (c) breast
cancer risk factors (for example, familial risk) may differ for pre-
menopausal women. We examined rates and trends for inva-
sive and in situ tumors separately, then stratified incidence by
several demographic and tumor characteristics, including race
(White, Black, or Asian/Pacific Islander), Hispanic origin, ER
and progesterone receptor (PR) status (ER+/PR+, ER+/PR-,
ER-/PR+, ER-/PR-, or other/unknown), histology (ICD-O-3 his-
tology codes for invasive ductal carcinoma [IDC] [code 8500],
invasive lobular carcinoma [ILC] [code 8520], invasive ducto-
lobular carcinoma [IDLC] [code 8522], or other/unknown
[codes 8000–8499, 8501–8519, 8521, and 8523–9989]),
and tumor size (diameter of largest focus less than 2 cm,
greater than or equal to 2 cm, or unknown). We categorized
race/ethnicity into the following groups: Asian/Pacific Islander,
Hispanic, African-American, and non-Hispanic White (hereaf-
ter referred to as White). Incidence rates were not subjected
to modeling for possible delays in reporting, since prior analy-
ses found that such adjustments had no substantial impact on
breast cancer trends or patterns [2].
We used SEER*Stat version 6.3.5 (National Cancer Institute)
to calculate annual age-adjusted breast cancer incidence
rates and corresponding 95% confidence intervals (CIs). All
rates are presented as cases per 100,000 person-years
unless otherwise noted. Statistical significance between
yearly rates was determined by comparing the CI overlap. The
Joinpoint Regression Program version 3.0 (National Cancer
Institute) was used to describe changes in quarterly incidence
trends within tumor subtypes by racial/ethnic group. Joinpoint
software fits a linear regression function to the data and then
determines between zero and three joinpoints, indicating sig-
nificant changes in the overall trend (significance level, P <
0.05). These significance tests use a Monte Carlo permutation
method [25]. All data were plotted on a semilogarithmic scale
to aid visual assessment of slope differences [26].
Results
For the period 1992–2004, nearly 244,000 cases of invasive
and 48,000 cases of in situ breast cancer in women over 50
years of age were reported to the SEER program. Table 1 out-
lines the demographic characteristics of these patients and
clinical characteristics of their tumors stratified by race/ethnic-
ity. Most of these tumors (79.3% of invasive and 77.1% of in
situ) occurred in White women. Regardless of patient race/
ethnicity, the majority of tumors were ER+/PR+, ductal histol-
ogy, and small (diameter of less than or equal to 2 cm), except
for among African-Americans, who were diagnosed with large
tumors more frequently than small tumors. Both Hispanic and
African-American women were more likely than Whites to
present with large or hormone receptor-negative tumors, and
Asians/Pacific Islanders were more likely than other racial/eth-
nic groups to have ductal rather than lobular or mixed tumors.Page 2 of 12
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Demographic and tumor characteristics of invasive and in situ female breast cancer cases (Surveillance, Epidemiology, and End 
Results-13)
Invasive
Asian/Pacific Islander Hispanic African-American Non-Hispanic White
n = 15,933 (6.5) n = 15,355 (6.3) n = 19,105 (7.8) n = 193,513 (79.3)
Demographics
Diagnosis year
1992 854 (5.4) 920 (6.0) 1,237 (6.5) 13,822 (7.1)
1993 851 (5.3) 869 (5.7) 1,231 (6.4) 13,732 (7.1)
1994 870 (5.5) 958 (6.2) 1,299 (6.8) 14,003 (7.2)
1995 984 (6.2) 995 (6.5) 1,356 (7.1) 14,333 (7.4)
1996 1,045 (6.6) 1,095 (7.1) 1,392 (7.3) 14,402 (7.4)
1997 1,253 (7.9) 1,067 (6.9) 1,453 (7.6) 15,289 (7.9)
1998 1,292 (8.1) 1,212 (7.9) 1,483 (7.8) 15,807 (8.2)
1999 1,373 (8.6) 1,264 (8.2) 1,550 (8.1) 16,048 (8.3)
2000 1,352 (8.5) 1,350 (8.8) 1,506 (7.9) 15,608 (8.1)
2001 1,491 (9.4) 1,327 (8.6) 1,526 (8.0) 16,033 (8.3)
2002 1,558 (9.8) 1,433 (9.3) 1,683 (8.8) 15,697 (8.1)
Tumor characteristics
Hormone receptor 
status
ER+/PR+ 8,242 (51.8) 6,619 (43.1) 6,941 (36.3) 101,364 (52.4)
ER+/PR- 1,707 (10.7) 1,558 (10.1) 1,921 (10.1) 21,653 (11.1)
ER-/PR+ 324 (2.0) 250 (1.6) 374 (2.0) 3,022 (1.6)
ER-/PR- 2,504 (15.7) 2,417 (15.7) 4,243 (22.2) 24,355 (12.6)
Other/unknown 3,156 (19.8) 4,511 (29.4) 5,626 (29.4) 43,119 (22.3)
Histology
IDC 11,780 (73.9) 10,204 (66.5) 12,824 (67.1) 128,393 (66.3)
ILC 748 (4.7) 1,121 (7.3) 1,190 (6.2) 18,663 (9.7)Page 3 of 12
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Other/unknown 2,562 (16.1) 2,878 (18.7) 3,912 (20.5) 31,494 (16.3)
Size
<2 cm 8,669 (54.4) 7,077 (46.1) 7,904 (41.4) 108,527 (56.1)
≥ 2 cm 6,076 (38.1) 6,674 (43.5) 8,711 (45.6) 66,515 (34.4)
Unknown 1,188 (7.5) 1,604 (10.4) 2,490 (13.0) 18,471 (9.5)
In situ
Asian/Pacific Islander Hispanic African-American Non-Hispanic White
n = 4,025 (8.4) n = 2,807 (5.9) n = 4,072 (8.5) n = 36,908 (77.1)
Demographics
Diagnosis year
1992 115 (2.9) 110 (3.9) 177 (4.3) 1,942 (5.3)
1993 163 (4.0) 117 (4.2) 181(4.4) 1,932 (5.2)
1994 173 (4.3) 138 (4.9) 212 (5.2) 2,043 (5.5)
1995 214 (5.3) 152 (5.4) 259 (6.4) 2,313 (6.3)
1996 219 (5.4) 160 (5.7) 238 (5.8) 2,411 (6.5)
1997 245 (6.1) 199 (7.1) 300 (7.4) 2,717 (7.4)
1998 292 (7.3) 237 (8.4) 335 (8.2) 3,182 (8.6)
1999 381 (9.5) 238 (8.5) 350 (8.6) 3,306 (9.0)
2000 358 (8.9) 257 (9.2) 383 (9.4) 3,344 (9.1)
2001 447 (11.1) 279 (9.9) 412 (10.1) 3,496 (9.5)
2002 527 (13.1) 287 (10.2) 375 (9.3) 3,497 (9.5)
2003 451 (11.2) 309 (11.0) 413 (10.1) 3,326 (9.0)
2004 440 (10.9) 324 (11.5) 437 (10.7) 3,399 (9.2)
Values in parentheses are percentages. ER, estrogen receptor; IDC, invasive ductal carcinoma; IDLC, invasive ducto-lobular carcinoma; ILC, 
invasive lobular carcinoma; PR, progesterone receptor.
Table 1 (Continued)
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Figure 1a shows that Asian/Pacific Islander (-8.5%) and His-
panic (-2.9%) women experienced statistically nonsignificant
incidence declines between 2001 and 2004 (247.3, 95% CI
234.8 to 260.3 in 2001 and 226.4, 95% CI 215.2 to 237.9 in
2004 for Asians/Pacific Islanders; 233.8, 95% CI 221.2 to
247.1 in 2001 and 227.0, 95% CI 215.4 to 239.1 in 2004 for
Hispanics). Rates among African-Americans were relatively
stable (0.5%) over the same period (312.0, 95% CI 296.4 to
328.3 in 2001 and 313.7, 95% CI 298.7 to 329.3 in 2004).
These results contrasted with the substantial decline
observed among White women, in whom incidence fell from
421.3 (95% CI 414.7 to 427.9) in 2001 to 360.9 (95% CI
354.9 to 366.9) in 2004, a 14.3% decline.
Joinpoint regression analysis of invasive breast cancer by
annual quarter of diagnosis suggested an incidence increase
among White women until the first quarter of 1999 (0.5% per
quarter, 95% CI 0.4% to 0.7%), stable rates from 1999 to
2002 (-0.4% per quarter, 95% CI -1.1% to 0.3%), and a sig-
nificant decline thereafter (-1.4% per quarter, 95% CI -1.8%
to -0.9%). By comparison, incidence in Asians/Pacific Island-
ers increased more dramatically from the third quarter of 1994
to the third quarter of 1997 (2.0% per quarter, 95% CI 0.7%
to 3.4%) then declined more gradually (-0.5% per quarter,
95% CI -0.8% to -0.3%) through 2004. In Hispanics, rates
increased by 0.4% (95% CI 0.1% to 0.7%) per quarter prior
to 2000 and decreased by 0.7% (95% CI -1.3% to -0.2%) per
quarter after 2000. Significant changes in incidence were not
detected among African-American women between 1992 and
2004 (-0.02% per quarter, 95% CI -0.1% to 0.1%).
Trends for in situ cancer
Incidence of in situ tumors remained constant during 2001–
2004 among Asian/Pacific Islander, Hispanic, and African-
American women (Figure 1b). In White women, rates
decreased 7.0% from 94.2 (95% CI 91.1 to 97.4) in 2001 to
87.2 (95% CI 84.2 to 90.2) in 2004. Joinpoint analyses sug-
gested that rates of in situ cancer increased during the first
half of the observation period, irrespective of race/ethnicity,
and then decreased in the first quarter of 2002 among Asians/
Pacific Islanders (-3.3% per quarter, 95% CI -5.5% to -1.0%),
a decline that began 3 years after the decreasing trend
observed among Whites (-0.5% per quarter, 95% CI -0.8% to
-0.1% after third quarter 1999). In contrast, rates for Hispanic
and African-American women stabilized during 1998–1999
and were constant through 2004.
Trends by tumor hormone receptor status
Figure 2 shows annual changes in hormone receptor-defined
breast cancer rates among women 50 years old or older by
race/ethnicity. Asian/Pacific Islander women experienced a
Figure 1
Breast cancer incidence among women 50 years old or older by tumor behavior, race/ethnicity, and year according to Surveillance, Epidemiology, and End Results-13
and End Results-13. (a) Trends for invasive breast cancer. (b) Trends for in situ breast cancer. All rates are age-adjusted to the 2000 US standard.Page 5 of 12
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attenuated than the significant 8.6% decline observed in
White women) in the rate of ER+/PR+ tumors, producing a
cumulative reduction of 7.6% between 2001 and 2004. An
increase in the incidence rate of ER-/PR- tumors occurred
among Hispanic women, in whom rates rose 26.8% from 34.6
(95% CI 29.9 to 39.9) to 43.9 (95% CI 39.0 to 49.9) during
the period 2001–2004, and among African-American women,
Figure 2
Invasive breast cancer incidence among women 50 years old or older by receptor status, race/ethnicity, and year according to Surveillance, Epide-miology, and End Results-13
miology, and End Results-13. (a) Trends for ER+/PR+ breast cancer. (b) Trends for ER+/PR- breast cancer. (c) Trends for ER-/PR+ breast cancer. (d) 
Trends for ER-/PR- breast cancer. (e) Trends for other/unknown breast cancer. All rates are age-adjusted to the 2000 US standard. ER, estrogen 
receptor; PR, progesterone receptor.Page 6 of 12
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87.4 (95% CI 79.6 to 95.8). ER-/PR+ tumors were uncommon
but appeared to decline consistently over the time period.
Distinctly increasing and decreasing trends in ER+/PR+
tumors were evident in Asians/Pacific Islanders (1.5% per
quarter, 95% CI 1.1% to 2.0% until the first quarter of 1998;
-0.3% per quarter, 95% CI -0.7% to -0.001%) but were not
detectable in Hispanics or African-Americans as compared
with trends in Whites (1.3% per quarter, 95% CI 1.1% to
1.5% from mid-1992 to mid-1999; -0.7%, 95% CI -0.9% to
0.4% per quarter thereafter). Increases in the incidence of ER-
/PR- tumors between 1992 and 2004 were observed for Afri-
can-American and Hispanic women only.
Trends by histologic subtype
Incidence rates for specific histologic subtypes did not
change appreciably between 2001 and 2004 in any racial/eth-
nic group except for Whites, in whom ILC dropped 17.3%,
IDLC 16.6%, and IDC 12.0% (Figure 3). Notably, due to the
small number of cases of ILC and IDLC breast cancer among
Asians/Pacific Islanders, Hispanics, and African-Americans,
rates were considerably more variable in minority groups than
in Whites.
Using Joinpoint regression, we found two distinct patterns
for ILC in Asian/Pacific Islander women: a statistically signif-
icant increase from 1992 to mid-1998 (1.8% per quarter,
95% CI 0.5% to 3.2%) followed by a nonsignificant
decrease from mid-1998 to 2004 (-0.9% per quarter, 95%
CI -2.0% to 0.2%). Trends for IDC were similar but more
moderate. The incidence rate of IDLC increased significantly
in Hispanic and Asian/Pacific Islander women across the
entire observation period (1.6% per quarter, 95% CI 1.2% to
2.1%, and 2.1% per quarter, 95% CI 1.5% to 2.7%, respec-
tively) and in African-Americans from 1992 to 2000 (3.4%
per quarter, 95% CI 2.6% to 4.2%), after which rates stabi-
lized (-1.1% per quarter, 95% CI -2.4% to 0.2%). Con-
versely, IDLC among White women rose by 2.6% (95% CI
2.4% to 2.8%) per quarter prior to 2002 then rapidly
declined at -2.8% (95% CI -3.7% to -1.9%) per quarter.
Trends by tumor size
Figure 4 shows average annual incidence rates according to
breast tumor size by racial/ethnic group. In Asian/Pacific
Islander women, incidence of small tumors fell from 136.7
(95% CI 127.5 to 146.4) in 2001 to 117.0 (95% CI 109.1 to
125.4) in 2004, a 14.4% decline comparable to the 16.8%
reduction seen in White women (248.2, 95% CI 243.2 to
253.4 in 2001 to 206.6, 95% CI 202.1 to 211.2 in 2004) (Fig-
ure 4). The rate of large tumors remained constant over the
same period in Asians/Pacific Islanders but dropped 10.2% in
Whites. There were no significant changes detected in His-
panics or African-Americans.
Joinpoint regression identified a progressive increase in the
incidence rate of small tumors among Asian/Pacific Islander
women from 1992 to mid-2000 (1.1% per quarter, 95% CI
0.8% to 1.5%) followed by a decrease from mid-2000 to the
end of the observation period (-1.6% per quarter, 95% CI
-2.4% to -0.8%). Incidence rates of small tumors in African-
Americans and Hispanics also increased initially (1.1% per
quarter, 95% CI 0.7% to 1.5%, and 1.0% per quarter, 95% CI
0.6% to 1.4%, respectively) then inflected in mid-1998 and
the third quarter of 1999, respectively, to decline more gradu-
ally. By comparison, three trends for small tumors were
detected in Whites: an increase from 1992 to mid-1999
(0.9% per quarter, 95% CI 0.8% to 1.1%), a nonsignificant
decrease from mid-1999 to 2002 (-0.4% per quarter, 95% CI
-1.2% to 0.4%), and a sharp decrease after 2002 (-1.8% per
quarter, 95% CI -2.4% to -1.2%). Rates of large tumors during
1992–2004 were constant among Asians/Pacific Islanders
and African-Americans, decreasing among Hispanics (-0.2%,
95% CI -0.4% to -0.04%), and disjointed among Whites
(0.6% per quarter, 95% CI -1.4% to 1.1% from 1992 to mid-
1994; 0.7% per quarter, 95% CI 0.2% to 1.2% from mid-
1994 to first quarter 1998; -0.6% per quarter, 95% CI -0.8%
to -0.5% from first quarter 1998 to 2004).
Discussion
Understanding the recent declines in breast cancer incidence
requires examination of trends by important mediators of
breast cancer heterogeneity, particularly patient race/ethnicity
and tumor subtype [1-3,6]. Prior quantifications of breast can-
cer incidence trends that did not stratify by race/ethnicity may
have been biased by changing racial/ethnic composition. In
fact, this analysis did find substantial racial/ethnic variation in
recent breast cancer incidence trends among women older
than 50 at diagnosis, with attenuated declines among Asian/
Pacific Islander and Hispanic women and no significant drops
among African-American women. For the particular population
subgroups with observable reductions, rates of hormone
receptor-positive, lobular, and small tumors decreased most
markedly. Incidence of in situ tumors did not change notably
for any non-White group studied.
Racial/ethnic patterns of change speak to the two major
hypotheses advanced thus far to explain the recent breast can-
cer declines: (a) the widespread discontinuation of postmeno-
pausal estrogen/progestin HT in the second half of 2002 [1-
3,12-16] and (b) the presumed effects of mammography sat-
uration [2,5]. HT was once the most commonly used drug
among US women, with prescriptions peaking at 92 million
per year in late 1999 or early 2000, after which growth in pre-
scription rates flattened, presumably due to the release of null
results from the Heart and Estrogen/Progestin Replacement
Study (or HERS) in 1998, discouraging preliminary reports
from the WHI, and restrictive guidelines for HT use dissemi-
nated by the American Heart Association [12,27-29]. This pla-
teau in HT prescriptions was observed among all racial/ethnicPage 7 of 12
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from the WHI precipitated an immediate and large decline in
HT prescriptions, estimated as 37% to 72% in various
populations [12-16]. The magnitude of these relative reduc-
tions was comparable among Asians/Pacific Islanders, Afri-
can-Americans, and Whites [30]. A second but not mutually
exclusive explanation for observed incidence trends involves
population saturation of mammographic screening programs
[2,5]. Theoretically, breast cancer incidence, especially rates
of small and in situ tumors, should plateau or decline once the
Figure 3
Invasive breast cancer incidence among women 50 years old or older by tumor histology, race/ethnicity, and year according to Surveillance, Epide-miology, and End Results-13
miology, and End Results-13. (a) Trends for ILC breast cancer. (b) Trends for IDC breast cancer. (c) Trends for IDLC breast cancer. (d) Trends for 
other/unknown breast cancer. All rates are age-adjusted to the 2000 US standard. IDC, invasive ductal carcinoma; IDLC, invasive ducto-lobular car-
cinoma; ILC, invasive lobular carcinoma.Page 8 of 12
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publications have reported small decreases in mammography
uptake between 2000 and 2004 among US women 50 years
old or older [31-33].
Overall, our data support a role for mass HT cessation in
explaining the incidence patterns described in this analysis.
The observation that incidence changes were most pro-
nounced for hormone receptor-positive, lobular, and small
tumors corresponds to the limited race/ethnicity-specific data
on HT prevalence and discontinuation. Baseline HT use was
most prevalent among Whites and progressively less common
among Asians/Pacific Islanders, Hispanics, and African-Amer-
icans, who were significantly less likely than other racial/ethnic
Figure 4
Invasive breast cancer incidence among women 50 years old or older by tumor size, race/ethnicity, and year according to Surveillance, Epidemiol-ogy, and End Results-13
ogy, and End Results-13. (a) Trends for tumors with diameter less than 2 cm. (b) Trends for tumors with diameter greater than or equal to 2 cm. (c) 
Trends for unknown tumors. All rates are age-adjusted to the 2000 US standard.Page 9 of 12
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[30,31,34-39]. California Health Interview Survey data sug-
gest that in 2001 21% of White, 19% of Asian, 13% of His-
panic, and 10% of African-American women older than 50
were current estrogen/progestin users. By 2003, these prev-
alence estimates were 14% in Whites, 8% in Asians and His-
panics, and a constant 10% in African-Americans [31,40].
Thus, at least in California, absolute changes in HT use were
most dramatic among Whites and Asians and least among
African-Americans.
Consistent with the evidence that HT acts as a late-stage pro-
moter of hormone-sensitive tumors [41], we detected drops in
the rates of ER+/PR+, but not ER-/PR-, tumors in Asian/Pacific
Islander and White women, the two largest groups of former
HT users [12-16]. Increases in the incidence rates of ER-/PR-
with stable rates of ER+/PR+ tumors occurred in the two
groups known to use HT less frequently prior to the WHI: His-
panic and African-American women. These groups have been
reported to have a higher risk of receptor-negative tumors than
White women [19]. Current or recent HT use has also been
associated with lobular, ducto-lobular, tubular, tubo-lobular,
and, to a lesser extent, ductal tumors [42-46]. While we lacked
adequate statistical power to examine trends for these rarer
histologic subtypes in non-White groups, the largest declines
among Whites occurred for lobular and ducto-lobular breast
tumors. Moreover, the substantial decreases in the rates of
small tumors among Asians/Pacific Islanders and Whites are
in line with evidence that current HT users are more likely to be
diagnosed with small but not large tumors when compared
with never-users [42]. Although women taking HT may have
better access to care and therefore be more likely to receive
mammograms, tumor size distributions are reported to be
comparable between screened and unscreened HT users
Molceular and genetic discov[42]. Molecular and genetic
studies indicate that tumors of different sizes may have distinct
etiologies, which are established prior to diagnosis [47].
Regardless, since HT appears to preferentially promote
growth of hormone-sensitive invasive tumors but not influence
risk of in situ lesions [11], reductions in the incidence rate of
small invasive tumors without substantial changes in the inci-
dence of in situ lesions in population subgroups who most
used HT are consistent with a major impact of mass HT dis-
continuation on overall trends.
Our findings do not clearly substantiate the hypothesis that
changes in mammographic screening primarily drove the
reductions in breast cancer rates. National behavioral risk
factor surveys suggest that the percentages of women meet-
ing mammography recommendations leveled off between
1998 and 2000 in all racial/ethnic groups [48,49], with subtle
reductions reported between 2000 and 2004 which were
larger for Hispanic (-6.2%) than White (-1.5%) women [48]. In
California, there was no difference in screening trends by HT
use status, with the percentages of women receiving mammo-
grams increasing 12.3% and 11.0% between 2001 and 2003
for HT users and non-users, respectively [31]. Additionally,
changes in mammography uptake cannot account for
observed drops according to tumor subtype. First, although
mammographic screening is more sensitive to receptor-posi-
tive than receptor-negative tumors, differences in detection
rates are not likely to be substantial enough to explain differen-
tial incidence declines by receptor status [50]. Second, mam-
mography is less sensitive to lobular and mixed lobular tumors
than ductal tumors because of the more diffuse presentation
of the former, so a putative change in screening would have
resulted in a larger drop in ductal than lobular tumors, particu-
larly among Hispanics, who had the greatest decline in mam-
mography use, a trend not evident in these data [18,42,50].
Third, reductions in mammographic screening would theoreti-
cally minimize lead time so as to reduce the diagnosis of small
and in situ tumors, which cannot be detected clinically. If mam-
mography saturation caused the majority of changes in breast
cancer incidence, we would anticipate equally large declines
in small and in situ tumors with subtle or no reductions in large
tumors. As reported by Jemal and colleagues [2] for US
women of all races combined, we found no apparent reduc-
tions in the rates of in situ cancer for US Asian/Pacific
Islander, Hispanic, or African-American women between 2001
and 2004.
Other proposed mechanisms are also unlikely to explain
recent breast cancer trends [51]. There has been no evidence
of abrupt changes in chemopreventive or other pharmaceuti-
cals (for example, tamoxifen, raloxifene, nonsteroidal anti-
inflammatory medications, and statins) relevant to breast can-
cer between 2000 and 2004 [1,48,51]. And while increased
detection of in situ tumors over the past two decades could
theoretically result in later declines in invasive disease, if in situ
tumors represent pre-invasive lesions, such a longstanding
process is unlikely to account for the dramatic reductions seen
over a 2-year period [51]. Thus, for now, widespread discon-
tinuation of HT remains the most plausible explanation for
reported declines in breast cancer incidence.
This study used the largest, most extensive population-based
cancer database available in the US. SEER registries collect
cancer incidence information according to high-quality and rig-
orous standards [52]. Even though we selected a study period
during which highly concordant hormone receptor assays
were used to determine ER and PR status [53] and there were
no major revisions in diagnostic criteria for histologic catego-
ries [18], tumor subtype classification may have differed
between pathologists. Similarly, temporal improvements in the
reporting of tumor receptor status to cancer registries may
have upwardly biased some of the incidence trends reported
for receptor-defined subtypes. Thus, the post-2002 declines
in ER+/PR+ tumors described here and elsewhere may have
underestimated the true drop.Page 10 of 12
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cancer registry data and may have influenced our analyses.
Studies investigating the validity of cancer registry race/eth-
nicity data substantiate excellent overall agreement between
SEER and self-reported classifications for non-Hispanic
Whites and African-Americans but intermediate agreement for
Hispanics and Asians [54,55]. For lack of appropriate popula-
tion denominators, we were unable to investigate trends
among Asian subgroups, which have previously been shown
to have differing incidence patterns [56]. Another limitation of
this analysis was its low statistical power to detect subtle
trends in particular breast cancer subtypes among Asians/
Pacific Islanders and Hispanics. We could not evaluate rates
for tubular breast cancer because of its low yearly incidence,
nor could we examine additional breast cancer subtypes such
as luminal A, luminal B, or HER2/neu-defined tumors because
SEER does not yet report these characteristics.
Conclusion
Reductions in postmenopausal breast cancer incidence
observed in the US were strongest in White women, interme-
diate in Asian/Pacific Islander and Hispanic women, and
absent in African-American women. In all groups, declines
were most evident for hormone receptor-positive, lobular, and
small tumors. While this and other ecologic analyses cannot
definitively speak to the influence of population-wide reduc-
tions in mammographic screening or other risk factors, dispro-
portionate declines in the incidence of hormone-sensitive
tumor subtypes among racial/ethnic populations that most
commonly used HT bolster the hypothesis that mass HT
discontinuation after mid-2002 was the predominant cause of
recent breast cancer declines. To further inform discussions
about the impact of population-level HT use on breast cancer,
cohort studies, including the WHI observational cohort,
should examine the relationship between timing of HT cessa-
tion (and possible resumption) and risk of specific breast can-
cer subtypes. Future surveillance of population-based breast
cancer trends must stratify findings by racial/ethnic group and
tumor subtypes.
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